TIL logo

Instil Bio, Inc. Common Stock


TIL: Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.


Show TIL Financials

Consumer Interest
SEC Filings

Recent trades of TIL by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by TIL's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Chimeric molecules providing targeted costimulation for adoptive cell therapy Jul. 11, 2023
  • Patent Title: Aseptic tissue processing method, kit and device Apr. 04, 2023
  • Patent Title: Aseptic tissue processing method, kit and device Apr. 04, 2023
  • Patent Title: Cells expressing recombinant growth factor receptors Dec. 20, 2022
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of TIL in WallStreetBets Daily Discussion

TIL News

Recent insights relating to TIL

CNBC Recommendations

Recent picks made for TIL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in TIL

Corporate Flights

Flights by private jets registered to TIL